Table 3 Subphenotype-specific treatment response in the reanalyses of outcomes in four different clinical ARDS trials
From: ARDS Subphenotypes: Understanding a Heterogeneous Syndrome
Intervention/trial cohort analyzed | Hypoinflammatory subphenotype response | Hyperinflammatory subphenotype response | |||
|---|---|---|---|---|---|
Outcome | Intervention | Control | Intervention | Control | |
High vs. low PEEP/ ALVEOLI* [27] | 90-day mortality | 24% high PEEP | 16% low PEEP | 42% high PEEP | 51% low PEEP |
Conservative vs. liberal fluid strategy/ FACCT* [29] | 90-day mortality | 18% conservative fluid strategy | 26% liberal fluid strategy | 50% conservative fluid strategy | 40% liberal fluid strategy |
Simvastatin/ HARP-2 [40] | 28-day survival | No difference | Improved survival with simvastatin (p = 0.008) | ||
Rosuvastatin/SAILS [41] | 90-day mortality | No difference | No difference | ||